一、董事离任的基本情况 二、董事离任对公司的影响 山东步长制药股份有限公司（以下简称"公司"）董事会于近日收到董事赵 超先生的书面辞呈，由于个人原因，赵超先生辞去公司第五届董事会非独立董事、 战略与投资委员会委员职务。截至本公告日，赵超先生未持有公司股份，与公司 不存在重大分歧，不存在未履行的承诺及义务。 证券代码：603858 证券简称：步长制药 公告编号：2025-195 山东步长制药股份有限公司 关于公司董事辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 姓名 | 离任职务 | 离任时间 | | 原定任期 | | 离任原因 | 是否继续在上 市公司及其控 | 具体职务 | 是否存在 未履行完 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 到期日 | | | 股子公司任职 | （如适用） | 毕的公开 承诺 | | 赵超 | 董事 | 2025 年 10 | 月 | 2027年 6 | 月 | 个人原因 | ...

10月17日消息，据步长制药（603858）公告显示，公司董事赵超因个人原因于2025年10月17日辞职，原 定任期至2027年6月28日。赵超辞职后仍担任总裁职务，且未持有公司股份。公司将尽快完成新任董事 补选工作。赵超在任期间勤勉履职，公司对其贡献表示感谢。 责任编辑：刘万里 SF014 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-198 山东步长制药股份有限公司 关于拟放弃优先受让控股子公司股权的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、交易概述 山东步长制药股份有限公司（以下简称"公司"或"步长制药"）于 2025 年 9 月 4 日召开第五届董事会第三十一次会议，审议通过了《关于拟放弃优先受 让控股子公司股权的议案》，赵路拟将其持有的控股子公司山东步长鼎晟药业有 限公司(以下简称"步长鼎晟"）3.00%股权以 4.2366 万元转让给谢继辉，郭玉彪 拟将其持有的步长鼎晟 1.00%股权以 1.4122 万元转让给谢继辉，蔡云飞拟将其 持有的步长鼎晟 1.00%股权以 1.4122 万元转让给何涛。公司同意放弃上述股权 转让的优先受让权。本次股权转让价格按照步长鼎晟净资产计算。步长鼎晟截至 2025 年 7 月 31 日净资产为 141.22 万元（未经审计）。上述股权转让完成后，公 司持有步长鼎晟 94.00%股权比例。具体内容详见公司 2025 年 9 月 6 日 ...

Core Viewpoint - The company announces the resignation of director Zhao Chao due to personal reasons, effective October 17, 2025, with his original term set to end on June 28, 2027 [1] Group 1 - Zhao Chao will continue to serve as the president of the company despite his resignation from the board [1] - The company will expedite the process of selecting a new director to fill the vacancy left by Zhao Chao [1] - The company expresses gratitude for Zhao Chao's contributions during his tenure [1]

Core Viewpoint - The announcement details a technical service contract signed between Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. and WuXi AppTec Co., Ltd. to enhance drug development capabilities and reduce clinical trial time and costs, which will not adversely affect the company's financial status or operational results [16]. Group 1: Contract Details - The total amount of the contract is 10,800,000.00 yuan, including a 6% tax, with payments to be made in installments as per the contract terms [3]. - The contract is valid for three years, starting from the date of signing, and will automatically extend until the completion of the project if it is not finished by the expiration date [9]. - All technical service results generated under this contract will belong to the company, which retains the rights to apply for patents [4]. Group 2: Parties Involved - Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. is a wholly-owned subsidiary of the company, holding 97.9545% of its shares, with a registered capital of 440 million yuan [10][11]. - WuXi AppTec Co., Ltd. has a registered capital of 1.05 billion yuan and specializes in drug development services [13]. Group 3: Financial Impact - The contract is expected to enhance the company's drug research and development capabilities, potentially leading to more efficient clinical trials and cost savings [16]. - The financial data of Sichuan Luzhou Buchang indicates total assets of 234,047.98 million yuan and a net asset of 21,929.81 million yuan as of June 30, 2025 [13].

Group 1: Corporate Leadership Changes - Fuyao Glass's chairman, Cao Dewang, has submitted his resignation but will continue to serve as a director and hold positions in some subsidiaries. His son, Cao Hui, has been elected as the new chairman [1] Group 2: Corporate Transactions - TBEA's subsidiary plans to acquire a 74.19% stake in Shuguang Cable for 946 million yuan to enhance its market share in high-end cable products [2] - Zhiguan Electric intends to purchase minority stakes in its subsidiary, Zhiguan Energy Storage, through a combination of share issuance and cash payment [5] - Yiyi Co. plans to invest 70.2 million yuan in a venture capital fund to strengthen its investment layout in the pet industry [6] Group 3: Corporate Performance - Rongzhi Rixin expects a net profit increase of 871.3% to 908.09% year-on-year for the first three quarters, driven by growth in the power, petrochemical, and non-ferrous industries [7] - Taihe New Materials' subsidiary, Minshida, reported a 28.88% increase in net profit year-on-year for the first three quarters [9] - Fuyao Glass reported a 28.93% increase in net profit year-on-year for the first three quarters, with a revenue growth of 17.62% [10] - Chunfeng Power's net profit increased by 30.89% year-on-year for the first three quarters, attributed to steady business growth [11] - Guobang Pharmaceutical's net profit grew by 23.17% year-on-year in the third quarter, despite a slight decline in revenue [12] - Tianan New Materials reported a 31.12% increase in net profit year-on-year for the third quarter, driven by growth in its subsidiaries [13] - Guangsheng Nonferrous expects to turn a profit in the first three quarters, with a projected net profit of 100 million to 130 million yuan, benefiting from rising rare earth market prices [14] - Aobi Zhongguang anticipates a net profit of approximately 108 million yuan for the first three quarters, marking a return to profitability [15] Group 4: Share Buybacks and Reductions - Jinchuan Group's shareholder, China Railway, plans to reduce its stake by up to 3% [16] - Yinlong Co.'s actual controller plans to reduce its stake by up to 1.96% [17] - Action Education's shareholders plan to collectively reduce their holdings by up to 230,000 shares [18] - Zhijiang Bio plans to repurchase shares worth between 60 million and 120 million yuan for employee stock ownership plans [19] Group 5: Significant Contracts - Buchang Pharmaceutical's subsidiary signed a technical service contract with WuXi AppTec for 10.8 million yuan, enhancing its drug development capabilities [20] - Zhongchao Holdings' subsidiary is involved in a national key project on new materials, focusing on high-temperature alloy casting [20]

（文章来源：证券日报） 证券日报网讯 10月16日晚间，步长制药发布公告称，近日，公司控股子公司四川泸州步长生物制药有 限公司与苏州药明康德新药开发有限公司（简称"药明康德"）签订《技术服务合同》，委托药明康德进 行药代动力学和毒理学试验项目。 ...

证券日报网讯 10月16日晚间，步长制药发布公告称，公司于2025年10月16日与成都农村商业银行股份 有限公司泸州分行（简称"成都农村商业银行泸州分行"）签订《保证合同》，为公司控股子公司四川泸 州步长生物制药有限公司（简称"泸州步长"）与成都农村商业银行泸州分行签订的《流动资金借款合 同》提供2，000万元连带责任保证。 （文章来源：证券日报） ...

Core Viewpoint - Company signed a technical service contract with WuXi AppTec to enhance drug development capabilities and reduce clinical trial time and costs [1] Group 1 - Sichuan Luzhou Buchang Pharmaceutical Co., Ltd. (subsidiary of Buchang Pharmaceutical) entered into a contract with WuXi AppTec for pharmacokinetics and toxicology testing [1] - The collaboration is expected to expand the company's drug research and development capacity and scope [1] - The agreement aims to ensure the smooth progress of projects while saving time and costs associated with clinical trials [1]

Core Viewpoint - Company announced a collaboration with WuXi AppTec to enhance its drug development capabilities and reduce clinical trial time and costs [1] Group 1 - Company’s subsidiary, Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd., signed a technical service contract with WuXi AppTec [1] - The collaboration is expected to expand the company's drug research and development capacity [1] - The agreement aims to ensure the smooth progress of projects by saving time and costs associated with clinical trials [1]